Hepatitis A virus transmission by blood products in the United States. Transfusion Safety Study Group.
To address the question of HAV prevalence and seroconversion in relation to clotting factor concentrates, we assayed an early serum for 339 hemophiliacs followed every 6 months by the Transfusion Safety Study in the period from mid-1985 until mid-1992. We found 58.4% positive around entry, with an age-specific prevalence that did not vary with age. In comparison to rates for anti-HIV-negative blood donors, they were significantly higher. Based on testing of subsequent sera, 11 hemophiliacs (7.8% of 141 susceptibles) changed their anti-HAV status from negative to positive. In 9 instances, positivity immediately followed the first dose of intravenous immune globulin. A possible seroconversion followed treatment with blood components, and a possible seroconversion followed intermediate-purity, solvent/detergent(SD)-treated factor VIII concentrate. Neither of these 2 patients was anti-HAV IgM positive, so that passively transferred antibody is possible. The high prevalence among hemophiliacs at entry must be further investigated by determining the expected background rate in a US population similar to the hemophilia patients, and by comparing anti-HAV prevalence associated with SD-treated and heat-inactivated concentrates.
Mosley
J W
JW
University of Southern California, Los Angeles 90032.
Nowicki
M J
MJ
Kasper
C K
CK
Donegan
E
E
Aledort
L M
LM
Hilgartner
M W
MW
Operskalski
E A
EA
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D016913:Blood Component Transfusion / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D015658:HIV Infections / Q000150:complications; D006506:Hepatitis A / Q000150:complications / Q000635:transmission*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D014481:United States